PrecisionLife Co-founder and Chief Business & Investment Officer, Rowan Gardner is speaking at Bio-Neuroscience in Amsterdam, the by-invitation event for key stakeholder groups crucial to the discovery, development and market launch of novel CNS therapeutics.
Rowan will be sharing some of PrecisionLife's clinical development expertise in a session dedicated to enhancing patient selection and clinical trials design in neurodegenerative diseases, where she will be joined by global leaders, innovators and decision-makers in neuroscience drug discovery and development.
PrecisionLife is pioneering the extension of precision medicine into neurological, psychiatric, and neurodegenerative diseases with multiple precision neuroscience R&D partnerships.
In drug development, we identify mechanistically defined subgroups of patients, who are most likely to respond to a specific drug treatment to enrich clinical trial design - making trials more targeted, faster to read-out, and more likely to be successful.
We've also reanalyzed Phase III clinical trial data from Top 5 pharma to explain unexpected drug response profiles, an approach which can be used to redesign and rescue trials that have previously reported sub-optimal efficacy outcomes.
Discover more
- Join Rowan at Bio-Neuroscience
- Read about our unique approach which is driving a new generation of precision neuroscience
- Find out how PrecisionLife is optimizing, de-risking and accelerating clinical development in complex chronic diseases
